Rhumbline Advisers Arrowhead Pharmaceuticals, Inc. Transaction History

Rhumbline Advisers

  • $121 Billion
  • Q3 2025

A detailed history of Rhumbline Advisers transactions in Arrowhead Pharmaceuticals, Inc. stock. As of the latest transaction made, Rhumbline Advisers holds 371,112 shares of ARWR stock, worth $15.3 Million. This represents 0.01% of its overall portfolio holdings.

Number of Shares
371,112
Previous 359,997 3.09%
Holding current value
$15.3 Million
Previous $5.69 Million 125.06%
% of portfolio
0.01%
Previous 0.01%

Shares

31 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 06, 2025
BUY
$14.71 - $34.49 $163,501 - $383,356
11,115 Added 3.09%
371,112 $12.8 Million
Q2 2025

Aug 12, 2025
BUY
$9.99 - $16.97 $140,039 - $237,885
14,018 Added 4.05%
359,997 $5.69 Million
Q1 2025

Apr 08, 2025
SELL
$12.74 - $21.53 $437,810 - $739,878
-34,365 Reduced 9.04%
345,979 $4.78 Million
Q4 2024

May 29, 2025
BUY
$17.7 - $26.34 $608,260 - $905,174
34,365 Added 9.93%
380,344 $7.15 Million
Q4 2024

Jan 30, 2025
BUY
$17.7 - $26.34 $140,042 - $208,402
7,912 Added 2.12%
380,344 $7.15 Million
Q3 2024

Nov 12, 2024
SELL
$19.36 - $29.54 $205,157 - $313,035
-10,597 Reduced 2.77%
372,432 $7.21 Million
Q2 2024

Aug 01, 2024
BUY
$21.87 - $28.24 $238,907 - $308,493
10,924 Added 2.94%
383,029 $9.95 Million
Q1 2024

May 09, 2024
BUY
$27.21 - $39.48 $1.35 Million - $1.96 Million
49,736 Added 15.43%
372,105 $10.6 Million
Q4 2023

Feb 08, 2024
SELL
$21.2 - $31.03 $392,157 - $573,992
-18,498 Reduced 5.43%
322,369 $9.86 Million
Q3 2023

Nov 09, 2023
SELL
$26.2 - $36.08 $72,233 - $99,472
-2,757 Reduced 0.8%
340,867 $9.16 Million
Q2 2023

Aug 08, 2023
SELL
$25.16 - $41.38 $46,822 - $77,008
-1,861 Reduced 0.54%
343,624 $12.3 Million
Q1 2023

May 11, 2023
SELL
$23.68 - $38.51 $17,665 - $28,728
-746 Reduced 0.22%
345,485 $8.78 Million
Q4 2022

Feb 14, 2023
BUY
$28.0 - $40.56 $507,808 - $735,596
18,136 Added 5.53%
346,231 $14 Million
Q3 2022

Nov 10, 2022
BUY
$29.63 - $48.31 $355,085 - $578,947
11,984 Added 3.79%
328,095 $10.8 Million
Q2 2022

Aug 11, 2022
BUY
$27.79 - $50.61 $739,464 - $1.35 Million
26,609 Added 9.19%
316,111 $11.1 Million
Q1 2022

May 12, 2022
BUY
$39.62 - $69.97 $267,593 - $472,577
6,754 Added 2.39%
289,502 $13.3 Million
Q4 2021

Feb 10, 2022
SELL
$58.09 - $82.51 $7,667 - $10,891
-132 Reduced 0.05%
282,748 $18.7 Million
Q3 2021

Nov 12, 2021
BUY
$58.38 - $84.96 $55,694 - $81,051
954 Added 0.34%
282,880 $17.7 Million
Q2 2021

Aug 05, 2021
SELL
$62.15 - $90.32 $438,219 - $636,846
-7,051 Reduced 2.44%
281,926 $23.3 Million
Q1 2021

May 06, 2021
SELL
$61.35 - $90.47 $531,475 - $783,741
-8,663 Reduced 2.91%
288,977 $19.2 Million
Q4 2020

Feb 10, 2021
SELL
$43.82 - $85.37 $94,081 - $183,289
-2,147 Reduced 0.72%
297,640 $22.8 Million
Q3 2020

Nov 12, 2020
SELL
$33.21 - $51.27 $1.11 Million - $1.72 Million
-33,478 Reduced 10.05%
299,787 $12.9 Million
Q2 2020

Aug 13, 2020
BUY
$26.12 - $43.27 $572,916 - $949,084
21,934 Added 7.05%
333,265 $14.4 Million
Q1 2020

May 06, 2020
BUY
$20.56 - $63.12 $122,475 - $376,005
5,957 Added 1.95%
311,331 $8.96 Million
Q4 2019

Feb 05, 2020
BUY
$28.14 - $73.01 $534,997 - $1.39 Million
19,012 Added 6.64%
305,374 $19.4 Million
Q3 2019

Oct 23, 2019
BUY
$26.26 - $34.86 $87,078 - $115,595
3,316 Added 1.17%
286,362 $8.07 Million
Q2 2019

Aug 14, 2019
BUY
$17.43 - $28.82 $2.77 Million - $4.58 Million
158,770 Added 127.76%
283,046 $7.5 Million
Q1 2019

May 01, 2019
BUY
$12.05 - $20.18 $100,171 - $167,756
8,313 Added 7.17%
124,276 $2.28 Million
Q4 2018

Jan 31, 2019
BUY
$10.74 - $19.7 $398,969 - $731,815
37,148 Added 47.13%
115,963 $1.44 Million
Q3 2018

Nov 07, 2018
SELL
$14.0 - $20.3 $72,338 - $104,890
-5,167 Reduced 6.15%
78,815 $1.51 Million
Q2 2018

Aug 06, 2018
BUY
$6.37 - $14.02 $534,965 - $1.18 Million
83,982 New
83,982 $1.14 Million

Others Institutions Holding ARWR

# of Institutions
339
Shares Held
103M
Call Options Held
953K
Put Options Held
263K
View Full List

About ARROWHEAD PHARMACEUTICALS, INC.

ARWR Quotes by TradingView
  • Ticker ARWR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 105,849,000
  • Market Cap $4.37B
  • Description
  • Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes ARO-AAT, a RNA interference (RNAi) therapeutic candidate that is in Phase II clinical trial for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3, w...
More about ARWR
Track This Portfolio

Track Rhumbline Advisers Portfolio

Follow Rhumbline Advisers and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Rhumbline Advisers, based on Form 13F filings with the SEC.

News

Stay updated on Rhumbline Advisers with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email